#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

Where this was said

Takeaways: supplement quality, individualized sleep treatment, and the importance of matching interventions to the biology of insomnia

At 53:00 · chapter starts 52:00

Quality control is the final filter that determines whether any supplement evidence applies to what you're actually buying. Supplement companies are not required to prove product quality before marketing, and Attia enumerates familiar failures: melatonin off by up to 478%, ashwagandha with withanolide inaccuracies in over half of tested brands, and the possibility of unlabeled contaminants or banned substances. The solution is third-party verification: USP Verified, NSF Certified for Sport, ConsumerLab, and Labdoor are the benchmarks he recommends. From there, Attia pulls together the episode's overarching argument. Sleep problems are not a single entity. They represent breakdowns in sleep pressure, circadian timing, hyperarousal, or sleep architecture — and most persistent treatment failures come from targeting the wrong mechanism. The behavioral foundation — aligning environment with biology, reducing hyperarousal, restoring confidence in sleep — always comes first. Medications can help, but only when used precisely and matched to the actual problem. Skip that diagnostic step, and you're guessing. And in sleep medicine, guessing is where most problems begin.